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overview of the use of models of prion disease, how they 
have evolved alongside the scientific questions, and how 
advancements in technologies have pushed the boundaries 
of our understanding of prion biology.
Abstract The understanding of the pathogenesis and mech-
anisms of diseases requires a multidisciplinary approach, 
involving clinical observation, correlation to pathologi-
cal processes, and modelling of disease mechanisms. It is 
an inherent challenge, and arguably impossible to generate 
model systems that can faithfully recapitulate all aspects 
of human disease. It is, therefore, important to be aware of 
the potentials and also the limitations of specific model sys-
tems. Model systems are usually designed to recapitulate 
only specific aspects of the disease, such as a pathological 
phenotype, a pathomechanism, or to test a hypothesis. Here, 
we evaluate and discuss model systems that were generated 
to understand clinical, pathological, genetic, biochemical, 
and epidemiological aspects of prion diseases. Whilst clini-
cal research and studies on human tissue are an essential 
component of prion research, much of the understanding 
of the mechanisms governing transmission, replication, and 
toxicity comes from in vitro and in vivo studies. As with 
other neurodegenerative diseases caused by protein misfold-
ing, the pathogenesis of prion disease is complex, full of 
conundra and contradictions. We will give here a historical 
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Glossary
Cellular prion protein (PrPC): Native, host-encoded, 
detergent soluble, protease-sensitive glycoprotein teth-
ered to the cell membrane by a glycosylphosphatidylin-
ositol (GPI) anchor. PrPC is encoded by the PRNP gene 
in humans and the Prnp gene in mice. It has predomi-
nantly α-helical structure, and it is expressed at high lev-
els in the brain.
Disease-associated prion protein (PrPSc): Misfolded, 
post-translationally modified (abnormal) isoform of 
PrPC, with a substantial β-sheet content. It is insoluble 
in non-denaturating agents and shows partial protease 
resistance.
Prions: Operational term to denote the transmissible 
agent of prion disease. According to the protein-only 
hypothesis, an essential constituent of prions is PrPSc.
Prion strains: Self-propagating prion protein confor-
mations or assembly states. They are characterised by 
distinct neuropathological and biochemical profiles that 
can be maintained even after passage through an inter-
mediate mammalian species with a different PrP amino-
acid sequence.
Species barrier/transmission barrier: Barrier that lim-
its cross-species infection, resulting in reduced trans-
mission efficiency with lower attack rates and prolonged 
incubation periods.
Prion disease: Fatal neurodegenerative disorder, also 
known as transmissible spongiform encephalopathy, 
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affecting humans and animals, characterised by accu-
mulation of PrPSc in the brain. Human prion diseases 
develop sporadically can be inherited due to germ-
line mutations in the PRNP gene and can be acquired 
through infection with human or animal prions through 
various routes.
Creutzfeldt–Jakob Disease (CJD): Human prion dis-
ease usually presenting as a rapidly progressive neu-
rological disorder with hallmark features of dementia, 
ataxia, and myoclonus.
Sporadic CJD (sCJD): The most common type of 
human prion diseases of unknown aetiology, occurring 
worldwide with an annual incidence of 1–2 cases per 
million. The phenotypic and neuropathological hetero-
geneity observed in sCJD is thought to be related to dif-
ferent prion strains and genetic factors, in particular the 
polymorphism on codon 129 of the PRNP gene.
Sporadic Fatal Insomnia (sFI): Clinical syndrome and 
neuropathology similar to FFI found in patients with 
PRNP 129MM genotype, but with absence of a D178N 
or any other mutation in the PRNP gene. First described 
in 1999.
Variably Proteinase-Sensitive Prionopathy (VPSPr): 
Sporadic prion disease of unknown aetiology first 
reported in 2008 with distinctive biochemical proper-
ties of PrPSc. In comparison with sCJD, PrPSc in VPSPr 
is less resistant to protease digestion. Neuropathol-
ogy of VPSPr includes microplaques in thalamus and 
cerebellum.
Iatrogenic CJD (iCJD): Acquired prion disease 
caused by transmission of prions through medical pro-
cedures and treatments with prion-contaminated human 
cadaveric derived growth hormone, dura mater or cor-
nea, or neurosurgical instruments.
Kuru: Prion disease acquired through dietary expo-
sure to prions through ritualistic cannibalism practiced 
mainly by the people of the Fore linguistic group, a pop-
ulation of the Eastern Highlands of Papua New Guinea. 
Clinically, it is characterised by progressive cerebellar 
ataxia and less prominently, dementia. Kuru peaked in 
the 1950s before cannibalism ceased.
Variant CJD (vCJD): Acquired prion disease due to 
dietary exposure to BSE prions first recognised in 1996. 
It is characterised by involvement of the lymphoreticular 
tissue and by a distinct neuropathological picture often 
presenting in young people, usually with a characteristic 
clinical phenotype.
Inherited prion diseases (IPD): They are caused by 
germ-line mutations in the PRNP gene and are inherited 
in autosomal dominant fashion with a high penetrance. 
They present as distinct clinical syndromes (GSS, FFI, 
and CJD) depending on the mutation.
Gerstmann–Sträussler–Scheinker disease (GSS): 
Inherited prion disease characterised clinically by 
adult-onset ataxia, postural abnormalities, and cogni-
tive decline. It is named after three clinicians, who first 
reported the disorder in 1936. A proline-to-leucine sub-
stitution at codon 102 (P102L) of human PrP is the most 
common mutation associated with the GSS phenotype 
and was first reported in 1989.
Fatal Familial Insomnia (FFI): Inherited prion dis-
ease characterised clinically by disruption of the physi-
ological sleep patterns and is associated with a thalamic 
degeneration. It is caused by a PRNP D178N mutation 
on the allele harbouring methionine at polymorphic 
codon 129. FFI was first described in 1986 and was suc-
cessfully transmitted to mice in 1995.
Bovine spongiform encephalopathy (BSE): Prion dis-
ease in cattle. BSE was epidemic in the United Kingdom 
with a peak incidence in 1992. More than 180,000 cat-
tle were infected. Transmission of BSE prions through 
dietary exposure caused vCJD in humans.
Scrapie: Prion disease in sheep, known for more than 
two centuries. Scrapie was the first transmitted prion 
disease and scrapie prions and strains derived thereof 
have since been widely used in experimental studies.
Introduction
Prion diseases are rare transmissible disorders, caused by 
misfolded post-translationally modified form of the native, 
host-encoded form of prion protein, designated PrPC [2, 
12]. It is proposed that the conversion of PrPC into an 
abnormal isoform, commonly termed PrPSc, is causally 
related to neurotoxicity, which is thought to be a result of 
a combination of toxic intermediates [157], overload of 
protein clearance pathways [106], and formation of protein 
aggregates [39].
The finding that the scrapie agent is infectious, transmis-
sible, and resistant to proteinases, heat, and decontamina-
tion methods that modify nucleic acids and would normally 
kill any conventional microorganisms enabled Stanley 
Prusiner to formulate the protein-only hypothesis [146], 
previously proposed by Griffith [61] and to introduce the 
term “prion”—a small proteinaceous infectious particle 
devoid of nucleic acid. Subsequently, the PRNP gene and 
its product, PrPC, were identified [12, 36, 131]. It is now 
widely accepted that PrPSc, the disease-associated isoform, 
aggregates and deposits in the brain, where it causes neu-
rodegeneration. An enigmatic property of prions is the 
existence of strains which are associated with distinct neu-
ropathological disease patterns and biochemical properties 
and are maintained through passages into different species, 
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although often at a reduced efficiency, which has been 
termed species (or transmission) barrier [79]. Mutations in 
the open reading frame of the PRNP gene cause a spon-
taneous conversion of PrPC into the abnormal isoform and 
often result in neurodegenerative syndromes, but are not 
always transmissible.
This review will give an overview of the historical devel-
opment of models of prion disease, which has been gener-
ated to address the multiple aspects of prion disease. We 
will put the models in the context of the available tech-
nology and the scientific questions at the time. The use of 
model systems for a human disease usually aims at address-
ing specific biological questions, rather than being compre-
hensive or being a faithful replica of the human disease. 
We will describe here for which aspects these models are 
useful and where they fail to give an answer. Many models 
have been generated to address a specific hypothesis rather 
than replicating an existing disease, and some raise more 
questions than they answer. Whilst certain aspects can be 
addressed by cell culture or in cell-free systems in vitro, 
animal models remain a mainstay in prion disease research, 
as only these allow to study clinical phenotypes, neuro-
pathological characteristics, transmission barriers, and the 
role of pathogenic mutations. In this review, we will first 
present the most significant animal models that have been 
used for the study of prion disease. Genetically modified 
mice have given answers to many essential biological ques-
tions in prion disease and will, therefore, form a major 
part of this review. Then, we will briefly discuss ex vivo 
and in vitro studies. Some of the biological questions can 
only be addressed by a combination of animal models and 
methodologies and these are discussed in the second part 
of the review. The illustrations of this review then combine 
and integrate the systematic overview of the model systems 
with the biological question.
In this review, we will give the reader an overview, and 
a selection of references will provide guidance for further 
reading. It is not our aim and also not possible to give an 
entirely exhaustive list of references, and we, therefore, 
had to resort to citing the most commonly used models or 
approaches. Where necessary, we have given references to 
in-depth reviews on specific topics.
Animal models of prion disease: from monkeys 
to flies
Transmission of human prion diseases into primates
Inoculation of isolates of kuru and Creutzfeldt-Jakob dis-
ease (CJD) into primates [54, 55, 57] proved transmis-
sion of human prion diseases and provided a model for 
the reproduction of histological phenotypes of spongiform 
encephalopathy (Fig. 1). Even decades later, despite the 
growing importance of genetically modified mouse mod-
els, which provided increased versatility and better read-
out, primates continued to have a role in transmission stud-
ies: transmission of brain extracts from cattle with Bovine 
Spongiform Encephalopathy (BSE) into macaques estab-
lished the first pathogenetic link between BSE and variant 
CJD (vCJD) [101], by producing a pathological phenotype 
that was nearly identical to vCJD. In more recent studies, 
primate models are used in correlative studies looking at 
transmission properties of different prion strains [135], to 
establish the zoonotic potential of transmissible spongi-
form encephalopathies (TSE) other than BSE, such as natu-
ral scrapie [46], to assess transfusion safety through appli-
cation of specifically designed prion removal filters [104], 
or to estimate the risk of oral infection with the BSE agent 
[100]. Cynomolgus macaque monkey (Macaca fascicu-
laris) has remained a relatively popular choice for prion 
research in primates, due to their longevity, phylogenetic 
proximity to humans, similar digestive physiology, and 
their genetic similarity to humans, including homozygo-
sity for methionine at PRNP codon 129. The main limita-
tions for more experimental studies on primates are their 
expensive maintenance, duration of experiments, and ethi-
cal concerns.
Rodents (hamsters, mice, and bank voles): modelling 
transmission, disease mechanisms, and function of PrP
Hamsters used to be popular for many types of prion stud-
ies since the 1970s, but were gradually replaced by mouse 
models, due to the widespread availability of genetically 
modified mice in the 1990s, initially by transgenesis, fol-
lowed by the combination with the gene knock-out model 
and, more recently, the inducible expression and deletion 
of the Prnp gene. A niche model, the bank vole will also be 
briefly discussed here (Fig. 2).
Wild-type Syrian golden hamsters have been used in 
prion research for over four decades with the first transmis-
sion experiments in the 1970s. Hamsters have been invalu-
able for the understanding of anatomical and functional 
pathways of prion spread from the periphery and within the 
CNS [75, 80, 81]. Through these models, distinct proper-
ties of different prion strains have been identified and they 
helped understanding the species barriers [78]. Although 
hamsters are still occasionally used in prion research, for 
example, for investigating the distribution and spread of 
prions after peripheral challenge [35], the wide availabil-
ity and versatility of transgenic mouse models have made 
hamster models largely obsolete.
Bank voles, small rodents, have been added relatively 
recently to the models of prion research [29, 128]. Their 
susceptibility to prions originating from multiple different 
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species is thought to be encoded in the bank vole PrP at 
codon 109 [Methionine or Isoleucine (Ile)], which has 
been elegantly confirmed in mouse models expressing 
bank vole PrP (BVPrP) [188]. BVPrP with Ile at codon 
109 causes a spontaneous neurodegenerative illness in 
mice, possibly due to an inherent propensity to misfold 
[189]. Furthermore, the primary transmission efficiency 
of sCJD prions (MM1, MV1, and MM2, but not MV2 
and VV2 (Parchi classification [136], see also Fig. 3 for 
homologisation with the London classification) and the 
transmission of inherited prion disease (IPD) (V210I, 
E220K, A117V; P102L, and F198S) into bank voles is 
not dissimilar to that in humanised transgenic mice [128, 
141]. Importantly, in bank voles, the neuropathologi-
cal and biochemical strain properties are well preserved 
[128]. However, whilst these models show deposition of 
abundant abnormal prion protein in the brain [187], the 
neuropathological phenotypes and the biochemical char-
acteristics of the modelled IPD do not correspond well to 
the human pathologies.
Scrapie Kuru sCJD IPD iCJD BSE vCJD VPSPr
2016 IPD_j Wild type bank voles IC Pirisinu, 2016
2015 Scrapie Macaque (Cynomolgus) IC Comoy, 2015
2015 BSE vCJD Macaque (Cynomolgus) Blood Lescoutra-Etchegaray, 2015
2014 VPSPr Tg (HuPrP129VV/MM/MV) mice IC Notari, 2014; Diack, 2014
2014 Scrapie sCJD BSE vCJD Tg(bank vole PrP) mice IC Was, 2014
2011 Scrapie Wild type mice Aerosol Haybaeck, 2011
2011 Scrapie Tg (Tg20a) mice Aerosol Haybaeck, 2011
2009 IPD_i Tg (HuPrP-mut) mice* IC Asante, 2009
2008 Kuru Tg (HuPrP129VV) mice IC Wadsworth, 2008
2006 IPD_h Tg (HuPrP129VV) mice IC Mead, 2006
2006 vCJD Tg (HuPrP129VV/MM/MV) mice IC Bishop, 2006
2006 vCJD Tg (HuPrP129MM/MV) mice IC Asano, 2006
2006 vCJD Tg (HuPrP129MV) mice IC Asante, 2006
2006 sCJD IPD_g Wild type bank voles IC Nonno, 2006
2005 BSE Macaque (Cynomolgus) Oral Lasmezas, 2005
2002 sCJD BSE vCJD Tg (HuPrP129MM) mice IC Asante, 2002
2000 BSE Sheep Blood Houston, 2000
1997 sCJD iCJD BSE vCJD Tg (HuPrP129VV) mice IC Hill, 1997
1997 sCJD iCJD BSE vCJD Wild type mice IC Hill, 1997
1997 sCJD vCJD Wild type mice IC Bruce 1997
1996 BSE Macaque (Cynomolgus) IC Lasmezas, 1996
1996 BSE Sheep IC Foster, 1996
1996 IPD_f Tg (MHu2M) mice IC Telling, 1996
1995 sCJD BSE Tg (HuPrP129VV) mice IC Collinge, 1995
1995 IPD_e Tg (MHu2M) mice IC Telling, 1995
1995 IPD_d Tg (HuPrP129VV) mice IC Collinge, 1995
1995 IPD_c Wild type NZWmice IC Tateishi, 1995
1994 Kuru sCJD IPD_b iCJD Primates IC Brown, 1994
1993 Scrapie BSE Marmosets IC and IP Baker, 1993
1990 Scrapie Cale IC Gibbs, 1990
1989 sCJD Wild type mice IC Kitamoto, 1989
BSE (Wells, 1987) 1988 BSE Wild type mice IC Fraser, 1988
1980 Scrapie Kuru sCJD Monkey (Squirrel) Oral Gibbs, 1980
1975 sCJD Guinea pig IC and IP Manuelidis, 1975
iCJD (Duffy, 1974) 1973 IPD_a Chimpanzees IC Roos, 1973
1972 Scrapie Monkey (Cynomolgus) IC Gibbs, 1972
1968 sCJD Chimpanzees IC Gibbs, 1968
1968 Kuru Monkey (Spider) IC Gajdusek, 1968
1966 Kuru Chimpanzees IC Gajdusek, 1966; Beck, 1966
1961 Scrapie Wild type mice IC Chandler, 1961
1961 Scrapie Goat IC Pason, 1961
1939 Scrapie Sheep IC Cuille and Chelle, 1936-1939
Scrapie (~1750) ~1750
IPD (FFI)
(Lugaresi, 1986)
vCJD (Will, 1996)
Recipient Route Reference
First report of the
disease
Year Inocula
VPSPr
(Gambe, 2008)
CJD (Creutzfeldt, 1920 &
Jakob, 1921)
1920
IPD (GSS) (Gerstmann,
Straussler, Scheinker,
1936)
1936
(1928
1913)
Kuru (Gajdusek, 1957)
Fig. 1  History of the use of animal models of prion disease. The left 
column indicates when the diseases were first reported, starting with 
scrapie in the 18th century and CJD in 1920. The time line (second 
column) is not strictly chronological, but is aligned with the genera-
tion of relevant animal models. The subsequent columns, titled “inoc-
ula”, indicate the different forms of prions that were transmitted. The 
column “recipient” indicates the species and, where appropriate, their 
genotypes. To the right, the transmission route and the reference. 
The inocula in the column IPD are complex and are according to the 
following key: a CJD in patients with family history (specific muta-
tion not known); b E200K, D178N 129V, P102L, 5-OPRI, 7-OPRI, 
and 8-OPRI; c D178N 129M and 24 basepair deletion mutation on 
the same PRNP allele; d D178N 129M; e E200K; f D178N 129M; 
g E200K, V210I; h 6-OPRI; i P102L, A117V, and E200K; j P102L, 
A117V, and F198S; Tg (HuPrP-mut) mice recipients: *HuPrP-P102L, 
HuPrP-A117V, and HuPrP-E200K; abbreviations for routes of trans-
mission: IC intracerebral, IP intraperitoneal
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Mouse models: a history of milestones in prion research
The initial use of mouse models was, as with other ani-
mals, for the transmission and adaptation studies by serial 
propagation of sheep scrapie to wild-type mice (Fig. 1; 
Table 1), to understand the biology of the species barrier 
and of prion strains. Whilst initially done on inbred mice, 
this has significantly changed with the availability of trans-
genic models (Fig. 2; Supplementary Table 1). The first 
transgenic mice in prion research, published in 1989—sev-
eral years after the creation of the first transgenic animal 
in 1982 [134]—expressed hamster transgenes and were an 
important milestone towards the understanding of trans-
mission barriers and strains [163], as they for the first time 
allowed to circumvent the species barrier and demonstrated 
the relevance of the amino-acid sequence of the Prnp gene 
for the susceptibility to prions strains. Expression of the 
murine equivalent of the human P102L mutation was the 
first significant attempt to model IPD associated with the 
Gerstmann–Sträussler–Scheinker (GSS) syndrome. Mice 
showed neurodegeneration, but no distinctive prion pro-
tein accumulation as seen in humans with GSS. GSS brain 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
2016 KO TgBVDel TgBVSub TgBVSub TgBVSub TgBVSub TgBVSub TgBVSub TgBVSub TgBVSub TgBVSub TgIntCross TgIntCross
2015 TgHu TgHu TgHu TgHu TgHu TgHu TgHu TgHu TgMoSub TgMoSub TgMoSub TgMoSub TgMoSub TgHuSub (4x)
2014 TgHu TgHu TgHu TgHu TgHu TgMHDel TgMHDel
2013 TgHu TgMoSub TgHuSub
2012 TgMHu2M (17x) TgBV (7x)
2011 TgHu TgMoDel TgMHuSub
2010 TgMHu2M TgMoDel TgMoDel TgMoDel Tg-Prom TgIntCross
2009 TgHu TgHu KIHu KIHu KIHu KIHu KIHu TgMoSub TgMoSub TgHuSub TgHuSub TgHuSub TgHuSub
2008 KO TgHu TgMoSub
2007 KiHuIns TgKIHu TgKIHu TgKIHu
2006 TgHu TgHu TgHu KIHu KIHu KIHu KIHu KIHu KIHu TgKIHu TgKIHu
2005 TgHu TgHu TgMoDel TgMoDel Tg-Prom TgMoSub
2004 Tg-Prom TgMoDel
2003 TgMHu2M PrPFc2 PrPFc2 PrPFc2
2002 TgHu TgHu KIChM TgMoO TgMo ConKO ConKO TgMoAlt TgMoAlt TgMoAlt TgMoAlt TgMoAlt TgMoAlt
2001 KO KO
2000
1999 TgMoSub TgMoSub
1998 TgMoAlt TgMoAlt TgMoAlt TgMoDel TgMoDel TgMoDel TgMoDel TgMoDel TgMoDel TgMoIns
1997 TgHaSub TgHaSub TgHaSub TgHaSub TgMHuSub TgMHuSub
1996 KIHu TgMoO TgMoO TgMoSub TgMoSub TgMoSub TgMoSub TgMoAlt TgMoAlt TgMoDel TgMoDel TgMoDel TgMoDel TgHaSub TgHaSub
1995 KO KO TgHu TgMoSub TgMoSub TgMoAlt TgMoAlt TgMoAlt TgMHuSub TgHa TgHa
1994 KO TgHu TgHu TgMHu2M TgMoO TgMoO TgMoSub TgMoSub
1993 TgMHM2 TgMHM2 TgMHM2 TgMHM2
1992 KO
1991
1990 TgMoO TgMoO TgMoSub TgHa
1989 TgHa TgHa TgHa
1982 First transgenic mouse  model (not related to prion disease)
VBgTbuSoMgTaHgT
snIoMgT2MHMgT TgBvSub
leDVBgTtlAoMgTleDHMgT
morP-gTbuSaHgT
KO PrPFc2
ConKO TgIntCross
uHgTM2uHMgT
uHIKMhCiK
TgMHuSub TgKIHu
TgMo TgHuSub
TgMoO KIHuIns
TgMoDel
Tg mouse expressing hamster PrP
Tg Mouse/Hamster chimera
Tg Mouse/Hamster chimera with deleons in PrP
Tg mouse with single amino acid substuon in
hamster PrP (to model IPD)
Tg Mouse/Human chimera
Prnp knockout mouse
Tg condional Prnp knockout mouse
Tg mouse with deleons in mouse PrP
Knock in Mouse/Human chimera
Tg Mouse/Human chimera with PrP alteraon (to
model IPD)
Tg mose expressing mouse PrP
Tg mouse overexpressing mouse PrP
Tg mouse expressing bankvole PrP
Tg mouse with single amino acid substuon in
bankvole PrP (to model IPD)
Tg mouse with deleon in bankvole PrP (to model
IPD)
Tg mouse with mouse PrP fused to human IgG1 Fcγ
tail
Tg mouse with altered mouse PrP intercrossed
with different mouse models
Tg mouse expressing human PrP
Knock in mouse expressing human PrP
Tg and knock in mouse expressing human PrP
Tg mouse with single amino acid subtuon (to
model IPD)
Knock in mouse expressin human PrP with
inseron
Tg mouse with single amino acid substuon in
mouse PrP (to model IPD)
Tg mouse with inserons in mouse PrP
Tg mouse with mouse PrP various other
alteraons
Tg mouse expressing PrP under promoters
Fig. 2  Detailed overview of genetically modified models in prion 
research. 1982 denotes the year of the first report of the generation of 
a transgenic mouse. The first use of transgenic mice in prion research 
was in 1989. The legend explains the abbreviation used in the main 
graph. Multiple fields indicate the generation of multiple mouse lines, 
sometimes published in a single article (see also supplementary table 
for further details)
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Tg152 mouse 
129VV
Wadsworth
2008
Tg mouse
129VV
Bishop
2010
Squirrel 
monkey
Parchi
2010
Thalamus
Parchi
MM1
MV1
VV1
MM2
MV2
VV2
MM2B
London Type 1MM
Type 2
MM
MV
VV
Type 3 
MM
MV
VV
Type 4
MM
VV2
“B”
Type 3
Present Present Medium size –relavely large
Diffuse in the 
thalamus,
hypothalamus 
and occasionally
brainstem. Diffuse 
and occasional 
plaques in the 
corpus callosum.
Punctate and 
diffuse. In the 
cerebral cortex 
most dense 
staining in deep 
layers.
Synapc and focal 
small plaque-like 
deposits. In the 
cerebral cortex 
most dense 
staining in deep 
layers.
unglycosylated
monoglycosylated
diglycosylated 36
30
21
19
kDa
Most severe
Least severe
Human
129VV2
Parchi
1999
Most severe
Least severe
a
b
c
d
e
Abnormal prion protein IHC
Vacuole size
Parchi
London
203Acta Neuropathol (2017) 133:197–222 
1 3
extracts could be propagated within the same strain of mice 
[69], but not into inbred wild-type CD1 mice [70]. This 
model expressed human Prnp transgenes on a background 
of murine Prnp sequences, and this caused a significant 
interference of the transgenic prion protein with its endog-
enous homologue (Table 1). A further milestone in prion 
research followed in 1992 with the generation of the Prnp 
knock-out (Prnp0/0) mouse [28] (Fig. 2), which not only 
demonstrated the requirement of the normal host prion pro-
tein to propagate prions [155], but also set the foundation 
to a nearly limitless numbers of models expressing a mul-
titude of transgenes without interference of the endogenous 
protein. Weissmann, the creator of the mouse has befit-
tingly phrased it “a mouse to remember” [190]. Economi-
cal animal maintenance and the continuous advances in 
gene editing and manipulation techniques have made mice 
a widely accepted and preferred model system, not only in 
prion research, but nearly universally in life sciences. New 
mouse models are continuously generated to address the 
biology of strains, function of PrP, transmission barrier, and 
with attempt to recapitulate human disease. The following 
paragraphs will outline the role of wild-type inbred strains 
of mice, the role of knock-out, transgenic and gene targeted 
mice in modelling human prion disease, and the function 
of PrP.
Inbred strains of wild‑type mice
The commonest inbred strains used in prion research are 
C57Bl/6L, C57Bl/6N, C57BL/10, FVB, and 129/Ola, and 
nowadays, less commonly used strains are RIII, VM, NZW, 
and CD1. Initially, wild-type mice were used to transmit 
sheep scrapie and to generate and adapt scrapie strains for 
further propagation (Fig. 1). For example, the strain ME7 
was the result of the transmission of natural scrapie of Suf-
folk sheep directly into mice. In contrast, other commonly 
used strains 22L, RML, and 79A, all distinct from ME7, 
share a common origin in that they were all derived from 
the Moredun Institute’s sheep scrapie brain pool (reviewed 
in [168], and a detailed experimental characterisation is 
given in [97]). Likewise, many of these inbred mouse 
strains were also used, albeit with much less success, to 
transmit and propagate human prions of various aetiolo-
gies, i.e., sporadic, inherited, and acquired forms, includ-
ing vCJD [26, 64, 83, 172]. The species barrier between 
humans and mice (also described as transmission barrier) 
results in low attack rates and markedly prolonged incuba-
tion periods. At the same time, the recognition of the exist-
ence of a species barrier was an important milestone as it 
eventually led to the generation of “humanised” transgenic 
mice and also to the transgenic mapping of the regions of 
the prion protein relevant for transmission barriers.
PrP knock‑out mice (PrP‑null mouse, Prnp0/0): a 
breakthrough in prion research to understand the role 
of PrPC
Since the publication of the first Prnp knock-out or Prnp 
null (Prnp0/0) mouse in 1992 [27, 28, 155], seven additional 
Prnp0/0 models have been reported as of 2016 (Fig. 2; Sup-
plementary Table 1). All these models lack significant regions 
of the Prnp open reading frame and they have in common 
that they do not express PrPC. The two first published models 
were generated in Zürich (hence termed ZH or Zrch I Prnp0/0) 
and in Edinburgh (Edbg Prnp0/0 [109]) and had only minor 
phenotypes [179] [Fig. 4(9)], whilst a model from Nagasaki, 
Japan (Ngsk Prnp0/0) developed ataxia, caused by a progres-
sive loss of cerebellar Purkinje cells [156]. It was later found 
that this was caused by the deletion of a splice acceptor in 
intron 2 of the Prnp gene, which causes an intergenic splicing 
event and overproduction of the transcript of a gene named 
Doppel or Dpl [124]. Expressed under normal circumstances 
at very low levels, Dpl is massively upregulated in the brain 
of Ngsk Prnp0/0 mice due to the high activity of the Prnp pro-
moter and results in the expression of Doppel protein in the 
CNS. A number of studies have then shown the role of Dop-
pel protein in experimental neurodegeneration (for example, 
see [154]), and functionally intriguing links with truncated 
PrPC, which causes a similar cerebellar phenotype, have been 
made (see below), but a direct relevance to human neuro-
logical diseases could never be established [117]. Other con-
founding factors were the embryonic stem cells and breeding 
schemes used for the generation of Prnp0/0 mice. The most 
popular embryonic stem cell lines are derived from the mouse 
129Ola strain, whilst mouse lines are maintained in non-129 
backgrounds. Using gene editing of C57BL/6J fertilised 
oocytes [130], a new Prnp0/0 mouse (termed PrnpZH3/ZH3) has 
been recently generated, which has eliminated all phenotypes 
previously reported, except chronic demyelination of periph-
eral nerves. Thus, the authors conclude that the demyelinat-
ing neuropathy is indeed the (only) effect of the Prnp loss of 
function [Fig. 4(8, 9)].
Fig. 3  Comparison of neuropathology and molecular strain types 
between an sCJD patient with PRNP codon 129 VV genotype and 
animal models. a Schematic representation of the severity of prion 
pathology and characteristic immunohistological pattern of synaptic 
and plaque-like abnormal prion protein deposits in the brain from 
sCJD patient with PRNP codon 129VV genotype. b Correspond-
ing molecular strain is VV2 (Parchi classification) or type 3 (Lon-
don classification). c Three animal models, two humanised mouse 
lines with 129V genotype, and a squirrel monkey. d Schematic rep-
resentation of the anatomical distribution of prion disease pathology, 
vacuolar size in the neuropil, and immunohistochemical pattern of 
abnormal prion protein deposits following disease development after 
intracerebral inoculation with the brain homogenate from the sCJD 
patient with 129VV genotype. e Corresponding molecular strain 
types in the animal models
◂
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Human PRNP transgenesis on the background 
of Prnp0/0 mice: a leap forward to understand human 
prion disease
The generation of Prnp0/0 mice was an essential tool to cre-
ate transgenic mice lacking the endogenous murine PrPC. 
Transmission of human prions into wild-type mice was 
fraught with significant transmission barriers and long 
incubation times [174], and this obstacle was effectively 
removed by intercrossing transgenic mice expressing full-
length human PrP or chimeric murine–human PrP (con-
taining components of human and murine genome) with 
Prnp0/0 mice (Fig. 1). These models had comparatively 
short incubation periods with a high attack rate, they devel-
oped clinical phenotypes, and were suitable for the study of 
transmission barriers from other species and from distinct 
human prion isolates, which they often faithfully replicated 
neuropathologically and biochemically. As a consequence, 
these models have a significant potential to test therapeutic 
compounds developed in silico and in vitro. In fact, these 
features render these models superior to those of many 
major neurodegenerative diseases, such as Alzheimer’s or 
Parkinson’s diseases, where clinical–pathological correla-
tion between the animal model and human disease often so 
far remain less compelling.
At present, at least 45 humanised mouse lines have been 
generated with combined transgenic and gene targeting 
approaches on the basis of Prnp0/0 mutants (Figs. 2, 3). The 
transgenic constructs not only carry the desired pathogenic 
mutations, but importantly the polymorphic genotypes at 
codon 129 (and more recently codon 219 and codon 127 
G > V modification [9]) of the PRNP gene. Over the years, 
the importance of a well-controlled genetic background 
has been increasingly recognised. Early studies often used 
mixed backgrounds (e.g., the 129V line (Tg152) or the 
129M line (Tg35) were initially kept in a FVB/N, C57BL, 
and 129Sv background [6]), whilst later, these lines were 
maintained on a strictly FVB-congenic background [9]. 
The comparability between different mouse lines is then 
further confounded by the different PrP expression levels. 
For example, Tg650 mice (HuM129, sixfold PrP expres-
sion) [16] inoculated with vCJD prions develop neuro-
logical disease with a 100% attack rate, but Tg35 mice 
(HuM129, two-fold PrP expression) [6] and knock-in mice 
(replacing murine with single copy human PrP) [18] only 
infrequently show neurological symptoms, whilst histo-
logical and biochemical examination clearly suggests sub-
clinical disease. Likewise, transmission of sCJD, into the 
“knock-in” MM, MV, and VV models [19], does not result 
in clinical disease when inoculated with sCJD MM2 strains 
(Parchi classification [136], see also Fig. 3 for homologi-
sation with the London classification). In contrast, Tg650 
mice with much higher PrP levels develop clinical signs of 
prion disease with a mean incubation time of approximately 
280 days [33]. Thus, for the purpose of disease modelling, 
for example, to assess drug effects on incubation time, PrP 
overexpression models have a clear advantage. This also is 
relevant for economical and practical reasons, such as cost 
of animal maintenance and the duration of typical research 
projects (e.g., life cycle of a grant or duration of a PhD). 
From a practical aspect, doubling the expression levels can 
often be relatively easily achieved by breeding mice into 
homozygous status. On the other hand, a model system that 
produces strictly physiological PrP expression levels, such 
as the knock-in model, does have a role for the study of 
function of PrP, but the limited lifespan of a mouse may 
preclude the development of a phenotype during lifetime.
Chimeric human/mouse models on the background of 
Prnp0/0 mouse
Since the generation of the first transgenic mouse line 
expressing chimeric mouse and human PrP was reported in 
1994 [174], over 20 different chimeric human–mouse lines, 
designated MHu2M (25% murine, 50% human, and 25% 
murine sequence) have been created. These lines differ 
in the amino-acid sequence of human PrP residues in the 
chimeric sequence, their PrP expression level, and incuba-
tion periods after inoculation with CJD prions [58]. These 
chimeric mice propagate human prions more “effectively”, 
and therefore, new chimeric transgenic lines are generated 
to further reduce the incubation times. This is achieved by 
altering the sequence similarity of chimeric PrP, by reduc-
ing human, and by increasing murine sequences. The 
shorter incubation time of MHu2M models renders them 
particularly suitable for bioassays of human prion infectiv-
ity and strain properties, but the main limitation is that they 
poorly recapitulate other aspects of human prion disease.
Conditional knock‑out/knock‑in models: the Cre‑loxP 
system
The use of the Cre/loxP recombination system enables 
“conditional” induction or inactivation of the gene of 
interest at a defined developmental time point, in a cell or 
tissue-specific manner, or both. The Cre-loxP-mediated 
knock-in gene replacement technique was first used in 
1996 to generate humanised PrP mice [82] (Fig. 2; Sup-
plementary Table 1) and has since been widely utilised. In 
addition to the generation of conditional knock-out [154] 
or knock-in mouse models [18], the Cre-lox system has 
been used in other modifications, for example, to generate 
mice with conditionally expressed soluble dimeric PrP to 
study the PrPC–PrPSc conversion process [121] [Fig. 4(11)]. 
A particularly successful model is the transgenic mouse 
expressing multiple copies of floxed (“flanked by LoxP 
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sites”) Prnp (Tg37 and Tg46) [107, 108], where upon Cre-
mediated recombination, the transgenically expressed PrP 
is excised at the age of 8–12 weeks. This is achieved by 
intercrossing Tg37 or Tg46 lines with mice expressing Cre 
recombinase under the control of the neurofilament heavy 
chain promoter (NFH–Cre/Tg37 and NFH–Cre/Tg46). The 
fairly precise onset of Cre expression made this a highly 
successful model for studying the role of PrPC to under-
stand the role of PrPSc toxicity [107, 195] and to evaluate 
potential therapeutic compounds [125, 126, 195].
Modelling the physiological and pathophysiological 
functions of PrP: expression of full length, partially 
deleted or tissue‑specific PrP
Following the generation of the Prnp0/0 mouse [28], a logi-
cal and scientifically important experiment was the rein-
troduction of PrP expression by transgenesis [53] (Fig. 2). 
The reintroduction of full-length PrP into Prnp0/0 mice 
proved the restitution of the propagation of prion disease. 
Mice expressing full-length PrP were designated Tga20 
(the letters “a” to “d” in the original publication indicate 
increasingly shortened Prnp open reading frames). Inocula-
tion of Tga20 mice with RML prions resulted in very short 
(approximately 60 days) incubation times and a very short 
disease duration (of only one or two days as compared to 
a more protracted course of the disease in wild-type mice 
expressing two copies of Prnp). In contrast, heterozygous 
mice expressing only one allele of Prnp (Prnp+/0) [53] had 
a significantly prolonged incubation times and a compara-
tively mild clinical course. Tga20 mice proved extremely 
popular for transmission experiments due to the very short 
incubation time for studies on neurotoxicity and prion 
spread within the brain or neural pathways into the brain 
[22, 23] and for studies of the kinetics of infectivity and 
prion protein accumulation [157, 158]. Other models over-
expressing PrP instead showed neurodegeneration and neu-
romuscular impairment [193].
Transgenic and gene targeted models: 
 
1. Prnp knockout mice and condional Prnp 
knockout mice 
2. Prnp knockout mice overexpressing PrPC or 
expressing altered PrPC on the background of  
murine, human, chimeric human/mouse, 
hamster, bovine or bank vole PrP sequences 
3. Mice expressing PrPC under the control of ssue 
specific promoters 
4. Mouse models of other pathways or cellular 
systems (e.g. Ubiquin Protease System, 
microglia) 
PrPSc-induced global translaonal repression in 
endoplasmic reculum 
Condional Prnp knockout mice 
PrPC-PrPSc conversion, structure, neurotoxicity, 
oligomers; role of GPI anchor in prion spread; prion 
strains; transmission barriers 
Transgenic mice overexpressing PrPC or expressing 
altered PrP from different species 
Role of neuronal PrPC in myelin maintenance 
Transgenic mice expressing PrPC under control of 
cell specific promoters (e.g. NSE, MBP or PLP ) 
Protecve role of microglia 
in prion disease 
Condional microglial 
Cx3cr1 knockout mice  
Funcon of PrPC 
Transgenic, knockout and 
condional Prnp knockout mice 
PrPSc-induced impairment of  
Ubiquin Protease System 
Transgenic UPS mouse model 
Role of astrocyte and 
oligodendrocyte PrPC in 
prion disease pathogenesis 
Transgenic mice expressing 
truncated mouse PrP, 
Hamster PrP 
1 
6 
5 
4 
3 
2 
10 
9 
8 7 
11 
Fig. 4  Schematic representation of the cellular and sub-cellular com-
partments and how PrP function and disease mechanisms are inves-
tigated with animal models. Key: 1 microglia, 2 astrocytes, 3 oligo-
dendrocytes, 4 myelinated axon, 5 neuronal cytoplasm, 6 ubiquitin 
protease system (UPS), 7 neuronal nucleus, 8 chromosomes, 9 Golgi 
complex, 10 Endoplasmic reticulum (ER), 11 blue globules represent 
native cellular prion protein PrPC, red globules represent misfolded 
prion protein PrPSc
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Mutants of PrP: deletions and point mutations
In addition to the re-expression of full-length PrP, Fischer 
et al. [53] generated multiple amino-terminal deletion 
mutants of the Prnp open reading frame to understand the 
function of PrP and to determine the minimum require-
ment for prion replication. These in-frame deletions were 
of progressive length (Δ32–93, Δ32–106, Δ32–121, and 
Δ32–134). This led to rather unexpected results, with a 
remarkable phenotype of progressive cerebellar degenera-
tion in the Δ32–121 and Δ32–134 lines [165] [Fig. 4(9, 
11)]. It was speculated that this phenotype could have been 
caused by the formation of hetero-dimers with full-length 
PrP [15] and of the Doppel protein interacting with the 
truncated PrP. However, no human disease corresponding 
to this intriguing phenotype has been identified yet.
The aim of introducing point mutations into the Prnp 
open reading frame is to generate models of human IPD. 
An in-frame 144 basepair insertion into the open read-
ing frame of the PRNP gene (6-octapeptide repeat insert, 
OPRI) in familial CJD [132] and the linkage of PrP mis-
sense variant, P102L, to the GSS syndrome were reported 
as early as 1989 [67]. A single amino-acid substitution in 
the mouse Prnp gene (101L, corresponding to the human 
102L mutation) was the first model of an IPD (Fig. 2). 
These mice showed a spontaneous neurological disease, 
and neuropathological findings were spongiform degen-
eration and gliosis similar to human disease [70], but criti-
cally, no amyloid plaques were formed, in stark contrast to 
the characteristic neuropathological phenotype in humans. 
Since then, technological advances have made it possi-
ble to create increasingly sophisticated model systems, 
as for example, the introduction of double replacement 
gene targeting strategy to generate multiple mouse strains 
with subtle PrP alterations to understand molecular patho-
mechanisms of inherited prion diseases and the function of 
anchorless PrP [37].
Ectopic and tissue‑selective expression of PrP [Fig. 4(2, 
3, 4)]
Most models expressing PrP ectopically were generated to 
understand the function of PrP in a cellular or tissue con-
text, i.e., to study in which cellular or organ system PrP can 
replicate and propagate infectivity, and eventually cause 
clinical or subclinical disease. Propagation of hamster pri-
ons selectively in astrocytes, but not in neurons was suf-
ficient to render mice susceptible to prion disease [152] 
[Fig. 4(2)]. Transgenic mice expressing PrP on lymphoid 
cells (in Prnp0/0 mice) led to the transmission of infectiv-
ity from the spleen into the brain that carried “sentinel” 
grafts derived from PrP-expressing neural stem cells [20]. 
More complex reconstitution experiments [85] in turn 
demonstrated that PrP expression on lymphoid cells is dis-
pensable to propagate prions. Ectopic expression of PrP on 
oligodendrocytes [144] [Fig. 4(3)] did not help propagating 
infectivity, whilst expression of truncated forms of PrP (or 
of Doppel protein) selectively in oligodendrocytes showed 
myelinotoxicity [151], not a surprising finding, given that 
this protein also causes Purkinje cell death [154]. Selective 
expression of full-length PrP in the axon was shown to be 
required for myelin stability in the peripheral nervous sys-
tem [24] [Fig. 4(4)].
Transgenic mice expressing PrP sequences 
of non‑human species
A wealth of transgenic mouse lines has been created 
expressing PrP sequences of species other than human. The 
first transgenic mouse containing Syrian golden hamster 
PrP was reported in 1989 ([163]. Since then, mouse mod-
els expressing bovine, ovine, porcine, guinea pig, elk, and 
bank vole PrP sequences have been made—available for 
research of transmissible spongiform encephalopathies of 
both humans and animals. Likewise, increasing numbers 
of intercrossed lines have been generated to investigate the 
role of immune system and microglia [Fig. 4(1)] in prion 
disease pathogenesis [167, 196]. Transgenic mouse lines of 
other model systems, particularly those related to immune 
system [24] and cellular processes [115], have shed light 
on important aspects of prion biology, but a comprehensive 
review of these models would be beyond the scope of this 
article.
Nematodes and flies
Unlike in research into other neurodegenerative diseases, 
invertebrate models, such as the nematode C. elegans and 
the fly Drosophila melanogaster, have so far been utilised 
very little in prion research. However, recent studies sug-
gest that these models hold a potential for studying, among 
other aspects, prion neurotoxicity [178], infectivity [177], 
and testing anti-prion compounds of sporadic and inherited 
prion disease [56].
Alternatives to animal models
Ex vivo models: organotypic slice cultures
Ex vivo experiments are performed on tissue taken out from 
live organisms, and transferred into an artificial environ-
ment. Organotypic slice culture is a popular ex vivo model 
and the first such assay for studying prion amplification and 
titration was published in 2008 [51, 52]. Since then, this 
model system, in particular murine cerebellar organotypic 
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cultured slices, has been used to study the physiological 
processes involved in prion formation, PrPC–PrPSc interac-
tions, prion-induced neurotoxicity, and to test efficiency of 
novel therapeutics. Organotypic slice cultures hold poten-
tial to bridge the gap between often highly complex in vivo 
and simpler in vitro models. However, the advantage over 
in vivo mouse models which provide a much more com-
plete picture on neuropathology, biochemistry, and behav-
iour has yet to be demonstrated. Even though initiatives to 
promote “3R” (refinement, reduction, and replacement of 
animal research) are supportive of such studies, the com-
plexity of culture conditions to maintain brain tissue slices, 
lack of standardisation, and a potentially difficult readout 
may have prevented a wider adoption in neurodegeneration 
research.
In vitro assays: a versatile, scalable, and reproducible 
alternative to animal models
Cell-based in vitro models are instead widely used in the 
research on the cellular biology of prion propagation, alone 
or in combination with in vivo experiments. The greatest 
benefits of cell culture models, in comparison with animal 
studies and organotypic slices, are low costs and experi-
mental simplicity, i.e., reproducibility, standardisation of 
culture conditions, and experimental readout. The success-
ful infection of the mouse neuroblastoma cell line N2a with 
RML/Chandler inoculum was reported in 1987 [150], and 
since then, a wide range of sub-clones have been devel-
oped and characterised, of which the PK1 and R33 lines 
are arguably most commonly used. At least 15 different 
other animal-derived neuronal and non-neuronal cell lines, 
including sub-clones, have been developed over years, 
and each of which shows a distinct susceptibility to prion 
strains, which on the other hand prevents direct comparison 
between lines (for review, see [105, 180]). As always, the 
simplicity and versatility of these assays have a downside: 
whilst cell culture studies have contributed enormously 
to the understanding of the mechanisms governing prion 
biology, many of these findings are not directly relevant 
to human disease. It is indeed a disappointment that many 
of the anti-prion compounds, which have been effective 
in vitro, have failed in subsequent in vivo studies.
Cell‑free assays, purified recombinant prion proteins, 
and synthetic PrP fragments: from the principle 
of protein folding to the development of assays
Since the first report of cell-free formation of protease-
resistant prion protein in 1994 [94], multiple tools and pro-
tocols have been developed to synthetise and purify recom-
binant mammalian PrP [102]. The most commonly used 
system for the synthesis of prion protein is Escherichia 
coli. Recombinant PrP of various species (human, mouse, 
bank vole, and Syrian hamster) has been generated, and 
many of these assays include deletions and truncations of 
PrP. Human recombinant PrP has been generated at full 
length [residues 23–231 (unglycolysated and lacking the 
GPI anchor)], and with various modifications, such as the 
expression of the globular domain only (residues 121–231 
or 90–231), amino-terminal flexible tail residues (23–120) 
[98], and Y145Stop (23–144) [99]. The objective of gen-
erating synthetic PrP is to study the physiological function 
of PrP, its role in disease pathogenesis, and conformational 
properties. Whilst the formation of prions from recombi-
nant PrP in a cell-free system has been demonstrated by 
some groups [102], a robust approach to reproducibly and 
systematically generate infectious prions from recombinant 
PrP in vitro has yet to be developed [161]. The systematic 
studies of conditions that lead to in vitro aggregation have 
also aided the development of cell-free assays for the detec-
tion of prions. It is beyond the scope of this review to dis-
cuss this in detail. Three major technologies, reviewed else-
where in great detail [10, 162, 192], are further discussed in 
the following.
Computer modelling and bioinformatics approaches
Advances in structural studies on molecules and compu-
tational modelling are the basis for the development of in 
silico molecular docking simulation methods, which allow 
analysing the interaction—binding modes and binding 
affinity—between various molecules. Thus, in silico com-
puter simulation technique is emerging as a powerful tool 
for screening novel therapeutics, including anti-prion com-
pounds [63, 133]. It is predicted that the use of in silico vir-
tual screening platforms for the identification of anti-prion 
compounds will continuously increase.
Model systems in the context of specific biological 
questions
In this section of the review article, the focus will be on 
models that could not be adequately discussed above. 
This is particularly relevant for crosscutting themes, and 
includes models which address specific biological ques-
tions or mechanisms.
Identification of the transmissible nature of the 
disease‑causing agent of scrapie and human prion 
diseases of different aetiologies (Fig. 1)
The transmissible nature of human prion diseases was first 
demonstrated in non-human primates with the transmission 
of kuru [54] and sCJD in 1968 [57]. These transmission 
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studies were encouraged by earlier studies of sheep scrapie. 
Whilst the transmissible and infectious nature of scrapie 
was long suspected, experimental studies were success-
ful only in 1936 when brain and spinal cord extracts from 
diseased sheep were transmitted into sheep or goat and 
the recipients developed scrapie after a 2 year incubation 
period, confirming its transmissible nature [48, 49]. These 
experiments were successfully reproduced a few decades 
later by Pattison [138]. Following the characterisation of 
the transmission of kuru, it became increasingly apparent 
that the agent, previously thought to be a slow virus, har-
boured rather unusual biological properties. These stud-
ies were carried out in primates [13, 54, 57] and led to the 
proposition of the protein-only hypothesis [61] with its sub-
sequent experimental verification in hamsters and mice [21, 
146, 147]. In comparison, the proof that vCJD is caused by 
BSE was established significantly faster, due to the avail-
ability of humanised transgenic mice [26, 64] also provid-
ing a significant additional insight into the pathogenesis of 
vCJD [45]. The transmission properties of prions derived 
from various inherited prion diseases have been exten-
sively studied in animal models, such as primates, inbred 
wild-type mouse strains, transgenic mice, and bank voles 
(Fig. 1) [4, 25, 44, 110, 118, 128, 140, 141, 172, 173, 175]. 
Prion transmission into knock-in humanised mice express-
ing PrP at various levels and carrying M129 or V129 alleles 
has been important in deciphering the basis for two dis-
tinct neuropathological and biochemical patterns of dural 
graft-related iCJD. These studies demonstrate that the 
observed neuropathological differences in these patients 
are best explained by their infection with distinct sCJD 
prion strains, and suggest that the human cadaveric dural 
graft pools may have been contaminated with prions from 
more than one donor [89]. More recently, the transmis-
sion of a newly identified form, variably protease-sensitive 
prionopathy (VPSPr), has also been confirmed in human-
ised mouse models [50, 129]. The observed extremely low 
transmission levels in one of the studies suggest that VPSPr 
has transmission properties distinct from other prion dis-
eases, such as sCJD and vCJD [50].
Models to understand species barriers
First evidence of an interspecies transmission barrier of pri-
ons and an experimental approach how to overcome it was 
demonstrated in 1961 when mice developed prion disease 
following inoculation with brain extracts from goats that 
had been inoculated with isolates from scrapie sick Suf-
folk sheep [32]. Following the primary transmission, which 
showed a species barrier, subsequent passages were 100% 
effective, with mouse strain specific incubation times [31]. 
A transmission barrier is defined as an incomplete pen-
etrance of the disease with prolonged incubation periods 
compared to the host [137]. The species (or transmission) 
barrier has been extensively modelled in transgenic human-
ised mice expressing either full-length human or chimeric 
human and mouse PrP genes (Figs. 1, 2). In vivo and 
in vitro studies have revealed that both the species-specific 
primary sequence homology of PrP (that is, differences in 
amino-acid sequence between host PrPC and donor PrPSc) 
and prion strain conformation are the major factors deter-
mining the species barrier [41]. To circumvent the species 
barrier and thus facilitate transmission of CJD, a number 
of different lines of transgenic mice have been produced. 
Mouse models expressing chimeric mouse–human prion 
protein transgenes have been particularly important in 
demonstrating the significance of the primary sequence of 
PrP to abnormal prion protein cross-seeding efficacy from 
different species. The relevance of sequence homology 
has subsequently also been shown in in vitro conversion 
assays [17, 95] and in experiments with scrapie-infected 
neuroblastoma cell lines [145]. The significance of prion 
strain conformation for interspecies transmission barrier as 
opposed to merely PrP sequence homology is highlighted 
in studies on yeast prions [171, 176], in study with recom-
binant PrP from various species [76] and more recently 
in studies with bank voles [128]. Substitution of a single 
amino acid in a critical region can be sufficient to change 
the species specificity and thus remove a species barrier as 
shown in studies with purified recombinant PrP23–144 of 
human, mouse, and Syrian hamster, where assets at posi-
tion 138 and 139 are determinants of species-dependent 
seeding specificity [181].
Transgenic mice overexpressing human PrP on the 
background of Prnp0/0 mice have been widely used to 
modulate and, when necessary, eliminate the species bar-
rier when transmitting common animal prion diseases, 
such as BSE, chronic wasting disease, (CWD) and scrapie. 
Whilst the zoonotic potential of BSE has been unequivo-
cally confirmed through transmission into transgenic mice 
expressing bovine, chimeric or human sequences [6, 64, 
164], a number of studies using various different mouse 
models overexpressing human PrP on the background of 
Prnp0/0 mice have demonstrated lack of such a potential for 
scrapie and CWD [96, 149, 159, 170]. More recent stud-
ies, however, utilizing PMCA in the same model (Tg440, 
overexpressing human PrP 129M) show that cervid PrPSc 
can, in fact, induce the conversion of human PrPC after the 
cervid PrPSc strain has been adapted by successive passages 
in vitro or in vivo [11]. In addition, the zoonotic potential 
of scrapie has recently been demonstrated in cynomolgus 
macaques following a 10-year incubation period [46] and 
in mice overexpressing human PrP [Tg340 (M129) and 
Tg361 (V129)] [30]. Whilst in mice, the efficiency of trans-
mission of the primary passage was low, subsequent serial 
passages of different scrapie isolates resulted in higher 
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attack rates and the propagation of prions which are phe-
notypically indistinguishable to sCJD strains (MM1 and 
VV2, respectively; Parchi classification, see also Fig. 3 
for homologisation with the London classification) [30]. 
This strain shift of the BSE/vCJD strain towards a human 
phenotype (i.e., sCJD) inevitably has potential public 
health implications [7], in that exogenous (i.e., potentially 
zoonotic) prions adapt towards, and may become indistin-
guishable from human strains, as shown also for CWD [11] 
or scrapie [30].
Prion strains
An enormous advantage of modelling prion diseases over 
any other neurodegenerative disorder is the ease of induc-
ing it through infection with prions, most commonly by 
intracerebral inoculation. Prions differ in their conforma-
tional states, which forms the basis of the general model 
of distinct prion strains [41]. In addition to well-charac-
terised strains of sporadic, acquired and inherited human 
prion diseases, those derived from hamster prions (Sc237 
and 263K), mouse-adapted BSE prions (301C and 301V), 
mouse-adapted scrapie prions, (RML, ME7, 139A, and 
79A), and anchorless prions derived from Tg44 mice 
(22L) have been extensively used to study human prion 
disease. A widely used animal strain into the research of 
both human and animal prion diseases is a mouse-adapted 
sheep scrapie isolate. It is derived from the prion strain 
RML, which was first described in 1961 by Chandler, and 
therefore, sometimes is also referred to as Chandler strain 
[32].
Distinct human prion strains, such as sCJD, vCJD, 
kuru, iCJD, VPSPr and sporadic Fatal Insomnia, not 
only differ in their biochemical and neuropathological 
patterns, but also have characteristic transmission and 
propagation properties which have been extensively 
studied in transgenic humanised mouse models [3, 18, 
19, 90, 111, 122, 129, 183, 186]. The knowledge gained 
through these studies is important particularly from a 
public health point of view, as this can help identify-
ing and characterising the origins of any new atypical 
strains. For example, transgenic mouse studies have 
shown that V2 PrPSc infection of a mouse with 129MM 
genotype (strain classification according to the Parchi 
classification [136], see also Fig. 3 for homologisation 
with the London classification) generates an unusual 
PrPSc with altered conformational properties, which 
retains the “memory” of V2 PrPSc and re-emerges and 
replicates rapidly when transmitted to a mouse with a 
129VV genotype. Such so-called trace-back studies are 
thought to be a reliable means for identifying the origin 
of prion strains [93]. Furthermore, based on the simi-
larities between neuropathological and biochemical fea-
tures of 129MM mice infected with the V2 PrPSc strain 
and those seen in one type of dural graft iCJD, it has 
been suggested that the combination of PRNP 129MM 
genotype, kuru plaques, and a specific PrPSc biochemi-
cal pattern may indicate an acquired aetiology of CJD 
[91–93].
Genetic susceptibility: models of PRNP gene 
polymorphisms and mutations
The human PRNP gene encodes methionine (M) or 
valine (V) at residue 129, which has a strong effect on 
the susceptibility to human prion diseases [119, 123]. 
In northern Europe 38% of the population are MM, 
51% MV and 11% are VV. Sporadic CJD occurs most 
frequently in MM homozygous individuals and it is 
also relevant in the acquired forms of CJD, most strik-
ingly in vCJD, where most clinical cases studied so far 
have been homozygous for methionine at codon 129 
of PRNP. A polymorphism at codon 127 (G127V) of 
PRNP has recently been determined as a resistance fac-
tor against the kuru epidemic and this observation also 
dismissed speculations of possible pathogenic muta-
tion that could have triggered the kuru outbreak [120]. 
In fact, it demonstrates that the polymorphisms at codon 
127 and 129 of PRNP are a population genetic response 
to an epidemic of prion disease and can be regarded as 
a powerful episode of recent selection in humans [120]. 
Another polymorphism, occurring in Asian populations, 
with an allele frequency of 6%, is E219K, which has 
been reported to have a protective effect for sCJD and it 
influences the clinical–pathological features of GSS with 
P102L mutation [66].
The importance of the polymorphisms as a disease mod-
ifier is also highlighted in the context of pathogenic muta-
tions of the PRNP gene, associated with IPD. More than 
40 different mutations have been described and comprise 
changes of the number of octapeptide repeats in the N-ter-
minal domain, PrP missense mutations causing an amino-
acid variant in most cases or rarely a premature stop codon 
[14]. The most common mutations are octapeptide repeat 
insertions and the point mutations P102L, D178N, E200K, 
and V210I [14], respectively. IPD comprises a range of het-
erogenous clinical presentations and neuropathological pat-
terns and represent approximately 15% of all prion diseases 
(for a summary of genotype–phenotype correlations, see 
[116]).
To understand the profound influence of com-
mon polymorphisms at residue 129 [6, 7, 183], the rare 
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polymorphism at residue 127 [9] and residue 219 [66] of 
the PRNP gene in susceptibility to acquired, sporadic and 
some inherited prion diseases and association of different 
polymorphisms with certain prion strains, transgenic, and 
knock-in humanised mouse models have been of particu-
lar importance. A comprehensive list of mouse models of 
human polymorphisms is given in Supplementary Tables 1 
and 2. Studies in mice expressing different combinations 
of 129M and 129V have been fundamental to understand 
the contribution of this polymorphism to susceptibility of 
different human prion strains. These models suggest that 
individuals with PRNP 129MV may be more susceptible to 
infection with vCJD prions than to cattle BSE prions and 
may present with a neuropathological phenotype distinct 
from vCJD [7]. BSE transmission into PrP 129VV mice 
caused clinical disease with no detectable PrPSc, a pheno-
type that is also seen in clinically affected BSE-challenged 
wild-type mice. Thus, BSE and vCJD prion infection in 
transgenic mice can result in the propagation of distinct 
molecular and neuropathological phenotypes dependent on 
host PrP residue 129 [7]. These data predict a critical role 
for PRNP codon 129 in governing the thermodynamic per-
missibility of human PrPSc conformation that can be inter-
preted within a conformational selection model of prion 
transmission barriers [183].
The recent mouse model for the protective effects of 
the V127 allele (which is seen only in combination with 
the M129 PRNP allele) [9] elegantly confirms that mice 
expressing the PrP V127 variant (on one allele, e.g., 
V127M129; G127M129) are unable to propagate kuru and 
sCJD prions, but they do propagate vCJD prions. Instead, 
mice homozygous for human PrP V127 (i.e., V127M129; 
V127M129) amazingly show a complete resistance to kuru, 
vCJD, sCJD, GH-iCJD, and DG-iCJD strains. It is obvi-
ous that there is a significant potential for further structural 
studies and eventually to develop effective drug interfering 
with prion replication.
The E219K polymorphism, prevalent in Asian popula-
tions and associated with a partial resistance to sCJD, has 
been replicated in a knock-in mouse model, which dem-
onstrated that the PrP 219K molecule is readily converted 
to PrPSc after challenge with vCJD and that the conver-
sion occurs even more effectively than in the 219E mol-
ecule. However, heterozygous 219E/K mice (“mismatch”) 
showed the least effective conversion, indicating so-called 
“heterozygous inhibition” [66]. With mismatching alleles, 
attack rates were much lower and incubation periods 
longer. Based on these findings, the “conformational selec-
tion” hypothesis has been proposed, where the transmis-
sion of infectious prions with shorter incubations periods 
is facilitated if the host prion protein can readily adopt the 
preferred conformation associated with the strain of the 
infected prion [40, 41, 182].
Models of PRNP gene mutations (Fig. 5): more 
promises than they can deliver?
The first genetic confirmation of the PRNP P102L mutation 
causing GSS in 1989 in two pedigrees [67] prompted the 
generation of mouse models for further study of the disease 
mechanism, understanding of phenotypic variability, and 
transmission properties [68, 70]. Since then, P102L models 
have been refined [4, 185] although have not always held 
the promise of full understanding of all aspects of the dis-
ease [5] with some results contradicting earlier studies [4]. 
A number of common point mutations (P102L [4], A117V 
[8], D178N, E200K [4, 73], as well as octapeptide insertion 
mutations [74], and mutations associated with formation of 
anchorless PrP [37]) have been modelled in mice. Whilst 
the most common approach has been the expression of a 
transgene on a Prnp0/0 background, also mice expressing 
murine, chimeric human/mouse, human, Syrian hamster, 
bovine, and more recently bank vole PrP sequences have 
been used. A comprehensive overview of available mod-
els expressing pathogenic PrP mutations is given in Fig. 5. 
With the development of different models, it has emerged 
that reproducing aspects of human IPD is far more chal-
lenging and unsatisfactory than modelling sporadic and 
acquired human prion diseases. The IPD models have one 
or more shortcomings: some either do not develop spon-
taneous disease at all, the disease is not fatal, the attack 
rates and transmission properties on further passages are 
variable, or the neuropathology and strain properties do 
not correspond to human equivalent. For example, the 
most recently published transgenic mice, generated with an 
attempt to reproduce human genetic prion disease express 
bank vole PrP containing corresponding D178N, E200K, 
and anchorless PrP mutations [187]. Although these mice 
develop transmissible, highly penetrant spontaneous dis-
ease with a neuropathological phenotype (vacuolar degen-
eration and abnormal PrP immunohistochemically detected 
deposits) distinct for each mutation, neither anatomical dis-
tribution nor neuropathological and biochemical findings 
correlate well with the human phenotype.
A range of mutant human PrP species (E220K, P102L, 
A117V, OPRI, D178N 129M, D178N 129V, F198S, and 
Y163X) has been transmitted into primates, bank voles, and 
transgenic mice expressing murine, human, or bank vole 
PrP. Except the truncating Y163X mutation, all other mutant 
prions are transmissible, but the resulting pathological phe-
notype does not correspond well to human disease. This dis-
crepancy has recently been reported and discussed in a P102L 
transgenic mouse model. Contrary to conclusions from the 
previous studies, 102L mutant prions are transmissible to 
transgenic mice expressing human PrP carrying the same 
mutation, but do not infect wild-type mice or mice expressing 
wild-type human PrP on background of Prnp0/0 [5].
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PrP point mutations directly influence PrPSc assembly 
and PrP primary structure significantly influences the phe-
notype of inherited prion disease. For example, a kindred 
with substitution at residue 211 (E211D) and individuals 
with an E211Q mutation, respectively, are reported to have 
remarkably distinct clinical phenotypes, neuropathology, 
and biochemical alterations [139]. The E211D mutation 
was associated with a GSS phenotype clinically and patho-
logically, whilst the E211Q mutation had a short disease 
duration and no amyloid plaques. Such strong influence of 
a single amino-acid substitution on the phenotype has also 
been confirmed in vitro and in vivo [139] and in vivo [73]. 
In keeping, phenotypical variations have long been known in 
families with pathogenic mutations. One explanation is the 
spectrum of involvement of protease-resistant wild-type PrP, 
as demonstrated in P102L IPD [185]. This study showed that 
in patients with P102L mutations, a substantial proportion of 
abnormal PrP is derived from the wild-type allele.
Tg69 (MHu2MPrP, P102L) (Telling, 
1995) 
P102L 
Human 
Mouse 
Cale 
Bank vole 
Tg27 and Tg33 HuPrP102L,129M  
(Asante, 2009) 
113LBoPrP-Tg037  
(Torres, 2013) 
PG14 (Mo-3F4) 
(Chiesa, 1998) 
9-OPRI 
TgSHaPrP(A117V)H (Hegde, 1999) 
TgSHaPrP(A117V)L (Hegde, 1999) 
A117V 
Tg(A116V), 128V  
(Yang, 2009) 
HuPrP117V,129V 
(Asante, 2013) 
D178N 
Tg(CJD) 128V (Dossena, 2008) 
ki-3F4-FFI (Jackson, 2009) 
Tg(FFI) (Bouybayoune, 2015) 
Tg15972, Tg15464, Tg15465, Tg15965 
(BVPrP,I109,D178N) (Was, 2016) 
T183A 
SHaPrPC(T183A) 
(Dearmond, 1997) 
E200K 
Tg(GPI-) (Chesebro, 2005) 
Tg8015 (GPI-) (Stohr, 2011) 
Tg(MoPrP-E199K)5182 (Telling, 1996) 
ki-3F4-CJD (Jackson, 2013) 
(TgMHu2M)E199KPrP 
(Friedman-Levi, 2011) 
MHu2MPrP(E200K) 
(Dearmond, 1997) 
Human/Mouse 
chimera 
Tg14205, Tg14210, Tg7253, Tg4253, 
Tg7271 (BVPrP,I109,E200K) (Was, 2016) 
A224V 
Tg 18807, Tg8387, Tg8421, 
Tg8422 (HuPrP, A224V), 129V 
(Was, 2015) 
Nonsense  
Human 
Mouse 
Bank vole 
Syrian hamster 
Tg(BVPrP,I109, ΔGPI) 
(Was, 2016) 
Tg23 and Tg49 HuPrP200K,129M 
(Asante, 2009) 
Disnct neuropathological changes following either spontaneous disease development or disease development aer 
inoculaon with prions  
Develop spontaneous disease 
Tg174 (MoPrP-101L) (Hsiao, 1990) 
Tg87 (MoPrP-101L) (Hsiao, 1994) 
Tg196 (MoPrP-101L) (Hsiao, 1994)  
Tg2866, Tg2247, Tg2862 (MoPrP-101L) (Telling, 1996) 
Prnpa101L, Prnpa 101PL (Manson, 1999) 
Prnp101L, SV40-101L (Moore, 1995) 
Tg(GSS)22 (Nazor, 2005) 
Clinical and neuropathological aspects not assessed in the original study 
Human/Mouse 
chimera 
MHu2MPrP (D178N) 
(Dearmond, 1997) 
Fig. 5  Transgenic mouse models of inherited prion disease. The 
open reading frame of the PRNP gene is represented in the centre, 
and the mutations that have been modelled in transgenic animals 
are shown above and below. On the left, the species PrP sequence of 
the transgene is shown, i.e., hamster, bank vole, mouse, and bovine 
sequences as well as chimeric constructs, such as human/mouse. The 
amber symbols next to the mutant indicate that the model developed 
a spontaneous disease and the green symbol indicates that there was 
a distinct neuropathological phenotype either spontaneously or fol-
lowing inoculation with prions. In one study, the clinical and neu-
ropathological aspects were not assessed (open symbol). The mouse 
lines with no symbol did not develop spontaneous disease and did not 
show distinct neuropathology Blue or red letters are simply for orien-
tation, to align with the point mutation shown in the centre
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Models of the formation, spread, toxicity, different 
strains of the abnormal prion protein, and cellular 
pathways
Bioassays: detection and measurement of infectivity 
titres
A robust, sensitive, and specific bioassay to detect prion 
infectivity is undoubtedly highly desirable for clinical diag-
nostics, epidemiological studies, and laboratory experimen-
tal assays. For clinical diagnostic purposes, a bioassay would 
have to be sensitive, specific, and should be achievable in a 
comparatively short turnaround time. Therefore, the trans-
mission into animals sensitive for human prion disease is not 
an option due to the long incubation times, comparatively 
high costs and ethical reasons. In addition, clinical studies 
would require validation and suitability of the assay for an 
accredited environment. Therefore, cell-free assays have the 
greatest potential for clinical purposes. The two most widely 
used cell-free assays are Protein Misfolding Cyclic Amplifi-
cation (PMCA) [34] and Real-Time Quaking-Induced Con-
version (RT-QuIC) [113]. PMCA uses PrPC for the ampli-
fication of PrPSc through repeated series of incubation and 
sonification. RT-QuIC uses automated quaking or shaking 
for the amplification of PrPSc from recombinant PrPC. Both 
cell-free-based assays detect PrPSc with remarkably high 
sensitivity. The limitations of PMCA are the risk of cross 
contamination and the generation of de novo PrPSc by off-
target amplification. RT-QuIC is limited by the readout and 
a non-infective end product , which makes it unsuitable, 
for example, to study effectiveness of decontamination of 
anti-prion compounds. A blood based assay, developed for 
the detection of vCJD in blood, and also of early stages of 
preclinical disease (Direct Detection Assay, DDA) [160] uti-
lises a solid-state binding matrix to capture and concentrate 
PrPSc, which is then detected immunologically. It is suitable 
for high-throughput screening in the surveillance of an at-
risk population [72] and for the detection of abnormal PrP 
conformers in animal models (CD1 mice, PrPC overexpress-
ing mice (Tga20), and Syrian hamsters) [160]. Scrapie cell-
based assays (SSCA), based on a cell line derived from N2a 
cells that are highly susceptible to RML prions, have been in 
development over several decades [88], and with standard-
ised methodology, they are suitable for automation and high 
throughput. Their refinement makes it possible to achieve 
high-throughput isolation of prions even to exceptionally 
high levels of purity with retained biological and biochemi-
cal prion strain properties [192].
Cell-based assays, in combination with animal studies, 
have been instrumental in understanding the dynamics of 
prion titres and the accommodation of toxic species in the 
progression of prion disease and for detailed correlation 
between neuropathological changes and prion titre [157, 
158]. Instead, classical transmission studies by serial dilu-
tion of an inoculum and subsequent transmission into large 
cohorts of animals, popular in the early times of prion 
research, and gold standard to determine titres in brains or 
brain regions [22] are becoming increasingly obsolete.
Formation of PrPSc and toxic oligomers in vivo
Conversion of PrPC into PrPSc is a post-translational pro-
cess, which occurs when PrPC reaches the extracellu-
lar domain. PrPC and PrPSc have identical amino-acid 
sequences but differ in their secondary and tertiary struc-
tures. PrPSc forms β-sheet-rich aggregates, which range 
from small, soluble oligomers to large insoluble fibrillary 
structures. The formation of PrPSc and the development of 
neurodegenerative changes require PrPC as a substrate [22]. 
Prion propagation in the brain involves two phases [157]. In 
the first phase, prions propagate exponentially andare not 
rate limited by the concentration of PrPC. They rapidly rise 
and reach a maximal titre. The titre is independent of PrPC 
concentration, i.e., there is no difference between Tga20, 
Prnp+/+ and Prnp+/0 mice. The flowing plateau phase deter-
mines the latency to clinical disease onset. The plateau 
phase is inversely proportional to the PrPC concentration. 
These studies [157, 158] demonstrate that propagation and 
neurotoxicity can be uncoupled, arguing that prions them-
selves are not directly neurotoxic, supporting claims of pre-
vious studies where prions generated by an infected neural 
graft did not cause degeneration of adjacent Prnp0/0 host tis-
sue [22]. Uncoupling of accumulated PrPSc and neurotoxic-
ity was also shown in the model of conditional inactivation 
of PrP expression in neurons, reversing clinical disease and 
halting spongiform changes and neuronal loss [107].
Cellular pathways as a response to prion toxicity
Cellular pathways implicated in misfolded protein response 
in prion disease can be located on the cellular surface or can 
be intracellular. PrPC molecules with internal deletions (for 
example, Δ94–134 and Δ105–125) cause neurodegenera-
tion [165]. The toxicity is more likely caused by abnormal 
activity on the neuronal surface, for example, interaction 
with NMDA receptors [77] rather than abnormal folding 
(discussed in detail in [38]). More relevant to the toxicity of 
misfolded proteins are intracellular pathways, the ubiquitin–
proteasome system, and endoplasmic reticulum (ER). Early 
functional impairment of the ubiquitin–proteasome system 
to degrade infectious prions has been shown in cell-based 
in vitro studies [103], in vivo in flies [127], and in trans-
genic mouse models of the ubiquitin–proteasome system 
[Fig. 4(6)] [115]. In the conditional knock-out Tg37 mouse 
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line and in wild-type mice, accumulation of PrPSc causes 
sustained over-activation of the PERK/eIF2alpha branch of 
the cellular defence pathway—unfolded protein response 
(UPR) with phosphorylation of eIF2alpha [Fig. 4(10)]. This 
leads to sustained repression of global protein synthesis 
(translational repression), with subsequent synaptic failure 
and neuronal loss [126]. The discovery of the involvement 
of these pathways in prion disease provides a scientific 
rationale for the pharmacological enhancement of the ubiq-
uitin–proteasome system and to target the ER unfolded pro-
tein response pathway in prion disease.
Models to understand the role of the immune system 
in the spread of prions
Whilst sporadic forms of prion disease have their origin 
within the CNS, acquired forms can involve the lymphore-
ticular system. The transmission of BSE prions through the 
food chain caused vCJD in humans. A highly distinctive 
and diagnostic feature of this prion strain was the colonisa-
tion of the lymphoreticular system [65], and this has gener-
ated widespread interest into the role of the immune system 
in prion diseases. Prior to the outbreak of vCJD, however, 
the role of the spleen in modulating neuro-invasion had 
been studied in scrapie-infected mice [81], where spleen 
removal reduced efficiency of peripheral prion infection, 
but had no effect once the infection had reached the CNS. 
The extensive use of transgenic mice, ectopically express-
ing prion protein on the lymphoid system or genetically 
modified immunosuppressed mice, has further pinpointed 
the role of individual components of the lymphoreticular 
system in prion spread [84, 85]. It is thought that prions 
invade the central nervous system from lymphoid organs 
by ascending spread via sympathetic and parasympathetic 
nerves [60, 112] and that anchored PrP is an essential com-
ponent for this pathway [86]. For more detailed reviews on 
the lymphoid system in prion spread, see [43] and [1]. The 
importance of the immune system has been successfully 
shown in preclinical studies with anti-PrP antibodies [194].
Models to investigate potential therapeutic approaches
The goal of biomedical research is to understand, prevent, 
and eventually treat human disease. This is no different for 
prion diseases, and developing effective treatments of prion 
diseases is a priority for many research teams. Clinical trials 
have to be evidence-based, and in vitro and in vivo models 
are essential to identify and characterise pathways that can 
be therapeutically targeted or can be used to validate “anti-
prion compounds” in preclinical studies. However, the ben-
eficial effects of compounds or reagents have not yet trans-
lated into effective clinical trials in patients [42, 62], but at 
least have led to important quantitative clinical data.
In silico computational modelling in combination with 
cell-based screening systems [71] can be the first-line 
experimental approach to identify potential anti-prion ther-
apeutics. This is usually further validated in animal models, 
where prion infected mice are challenged with promising 
candidate drugs [63, 125].
The use of monoclonal antibodies has been promising 
in preventing prion spread and in attenuating and delay-
ing clinical prion disease [194]. These studies were car-
ried out in wild-type mice of a defined genetic background. 
The safety of the use of monoclonal antibodies, however, 
has been a matter of considerable debate. Whilst toxicity 
of concentrated monoclonal antibodies was reported by 
some researchers [153, 166], others could not reproduce 
these findings [87], in particular when using physiological 
concentrations. A widely used transgenic model to assess 
therapeutic efficacy is the Tga20 mouse line that overex-
presses wild-type PrP. For example, in a recent study [63], 
Tga20 mouse line was used to identify, through iterative 
cycles of chemical design and synthesis, luminescent con-
jugated polythiophenes (molecules with high affinity for 
ordered protein aggregates) as potentially effective anti-
prion compounds.
The conditional knock-out mouse line Tg37 [107] 
was used in a study into the effect of a reduction of PrPC 
expression through therapeutic knockdown using RNAi 
in mice with established prion disease [195]). This model 
was also used to show positive effects of UPR inhibition by 
localized hippocampal PrP knockdown and through phar-
macological inhibition with the compound GSK2606414 of 
PERK kinase, a key mediator of the UPR pathway in the 
endoplasmic reticulum [125, 126]. The compounds tar-
geting the cellular downstream pathways—for example, 
PERK kinase inhibitor GSK2606414 causes severe toxicity 
in mice, making it unlikely that it will make it to a clinical 
trial in humans.
Given that innovative genetic strategies to halt or reverse 
progression of neurodegenerative diseases are emerging, 
it is possible that genetic manipulation with the end-result 
mimicking naturally occurring protective/prion-resistant 
single amino-acid substitutions may be a treatment of 
choice in prion diseases, particularly those of inherited 
aetiology. Validation and approval of such approaches 
undoubtedly will require extensive detailed in vitro cell-
based and in vivo animal studies in existing and newly gen-
erated model systems of prion infection.
Summary
The development and characterisation of models of prion 
disease have served a wide range of purposes, which 
have changed over time. The first models were used to 
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understand the transmissible nature of prions, well before 
even the concept of transmissible proteopathies was born. 
These models date back to the 1930s [47, 48] and culmi-
nated in the demonstration that kuru and CJD are trans-
missible neurodegenerative diseases in the 1960s [13, 54, 
55], leading to the hypothesis that scrapie is caused by an 
unusual self-replicating agent [61]. Nearly two decades 
later, using a combination of transmission studies and bio-
chemical evidence, Prusiner formulated the protein-only 
hypothesis [21, 114, 146]. The availability of genetically 
engineered mice in the 1980s then opened a wider area 
of research [68, 148] in that functional aspects of PrP and 
human mutations were modelled. The use of transgenic 
mice in prion research took-off after the generation of a 
mouse model devoid of PrPC, generated by Weissmann’s 
team [22, 27, 28, 155]. This model enabled the generation 
of mice devoid of endogenous PrP and was the basis for 
systematic modelling structural and functional aspects of 
PrP [20, 22, 53, 190, 191]. These mice were far superior 
to any previous model system to understand prion strains 
[2, 45], transmission barriers [184], tissue-specific effects 
of normal and abnormal PrP [59, 143, 144], the role of 
deletions, point mutations and modifications [165] affect-
ing structure, and glycosylation [37, 86, 142]. In parallel, 
powerful cell-based and cell-free in vitro systems have been 
developed [88, 160] and complemented the animal models. 
As pointed out in the paragraph on therapeutic approaches, 
the ultimate goal of model systems is to understand, pre-
vent, and treat human prion diseases. Thus, the model sys-
tems described in this review are only the beginning of 
the discovery phase. Whilst these model systems over the 
decades have become increasingly validated (through the 
use in several laboratories), they still have to live up to the 
promises of providing a robust and valid experimental plat-
form that can be used for drug discovery which translates 
well into a clinical trial.
Perspective (Fig. 6)
Studies with animal models and cell culture will most likely 
remain the mainstay in prion disease research for foresee-
able future. The use of rat models has been proposed due 
to advantages related to larger brain size and physiology, 
including cognitive and behavioural responses somewhat 
closer to human. However, the greatest potential undoubt-
edly lies in mouse models. These have proven to be inval-
uable in prion disease research and it is likely that further 
Generaon of 
new transgenic 
mouse models 
(e.g. intercrossed 
lines)
Generaon of 
other model 
systems (e.g. rats, 
flies)
Development of 
induced 
Pluripotent Stem 
Cells (iPSC)
Further 
advancements in 
cell culture and 
cell-free assays
Physiological funcon of PrPC
High resoluon structure of PrPC and PrPSc
PrPC-PrPSc interacon
Cellular pathways acvated / dysregulated by PrPSc
Neurotoxicity
Therapeuc targets and effecve and safe an-prion compounds 
Fig. 6  Future perspective in prion disease research: left increasing 
sophistication of transgenic models, and increasing access to gene 
editing methodologies is likely to have a significant role also in prion 
research. Left centre other species, in particular those which are easy 
to maintain and to manipulate, such as flies may play a role in mod-
els, in particular aiming at functional roles of PrP; increasing use 
of rat models due to the larger brain size. Centre-right a significant 
potential of induced pluripotent stem cells can be expected, and right 
in vitro cell-based and cell-free assays will play an important role 
in diagnostics, epidemiology, and safety of blood products and drug 
screening
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models will be able to address the increasingly complex 
questions of prion biology. The discovery of a compara-
tively straightforward methodology to induce pluripotent 
stem cells (iPSC) through reprogramming of fibroblasts 
(Takahashi and Yamanaka 2006) opened new avenues for 
the study of cellular pathomechanisms, early disease diag-
nosis, and screening of therapeutic compounds in probably 
almost all human diseases. Misfolded protein-associated 
neurodegenerative disorders, such as Parkinson’s disease 
and Alzheimer’s disease, are diseases, where iPSC derived 
from fibroblasts from skin or dura mater have been already 
actively used in research over the last decade providing 
novel insights into the molecular biology. Application of the 
reprogrammed cells in prion research, along with continu-
ous advances in the somatic cell reprogramming techniques, 
offers a promising tool for deepening the understanding of 
the molecular biology of prion infection, such as suscepti-
bility, modes and sites (neurones or glia or both) of prion 
replication, neurotoxicity, effects on cellular function, dis-
ease phenotypes and new drug screening, or, indeed, iPSC 
could serve as therapeutic agent themselves. Finally, sig-
nificant resources are put into advancing technological and 
methodological aspects of designing cell-free assays and 
high-throughput in silico screening methods. The power of 
bioinformatics and computational chemistry holds promises 
for the development of high-throughput in silico screening 
methods, but also are an important development to support 
the commitment to replacement, reduction, and refinement 
of animal research.
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